摘要
目的:观察和评价尿激肽原酶治疗急性脑梗死的临床疗效和不良反应。方法:2015年5月至2016年5月收治急性脑梗死患者160例,分成治疗组74例和对照组86例。对照组给予常规内科治疗,治疗组在常规治疗基础上给予尿激肽原酶0.15PNA,1次/d,两组均治疗14d。观察比较两组患者入院时和治疗后14d神经功能缺损程度评分(NIHSS)、治疗总有效率和不良反应发生率。结果:治疗组和对照组入院时NIHSS评分分别为(13.3±5.3)分和(13.1±4.9)分,组间差异无统计学意义(P>0.05);治疗后分别为(5.7±2.2)分和(7.8±2.5)分,组间差异有统计学意义(P<0.05)。治疗组治疗前后NIHSS评分差值为(7.1±1.6)分,对照组为(5.4±2.1)分,治疗组差值大于对照组(P<0.05)。治疗组总有效率为81.1%(60/74),对照组为53.5%(46/86),组间差异有统计学意义(P<0.05)。两组药物不良反应发生率比较差异无统计学意义(P0.05)。结论:尿激肽原酶治疗急性脑梗死安全、有效。
Objective： To observe and evaluate the clinical efficacy and adverse reaction of urinary kallidinogenase in the treatment of acute cerebral infarction. Methods： From May 2015 to May 2016, 160 patients with acute cerebral infarction treated in Pudong Hospital were divided into a treatment group with 74 eases and a control group with 86 cases. The control group was given the conventional treatment and the treatment group was given urinary kallidinogenase 0.15 PNA once a day on the basis of the conventional treatment. The two groups were treated for 14 days. The nerve function defect score（NIHSS）, the total effective rate and adverse reaction rate of the patients in the two groups were observed and compared at the admission to hospital and after treatment 14 days. Results： At the admission the NIHSS scores in the treatment group and the control group were（13.3±5.3）and（13.1±4.9）and there was no significant difference between the two groups（P〉0.05）. After treatment, the NIHSS scores in the treatment group and the control group were（5.7±2.2）and（7.8±2.5）and the difference between the two groups was statistically significant（P〈0.05）. Before and after treatment, the differences of NIHSS scores in the treatment group and the control group were（7.1±1.6）and（5.4±2.1）and the difference of the treatment group was greater than that of the control group（P〈0.05）. The total effective rates of the treatment group and the control group were 81.1%（60/74）and 53.5%（46/86）and there were statistically significant differences between the two groups（P〈0.05）. Conclusion： Urinary kallidinogenase in the treatment of acute cerebral infarction is safe and effective.
作者
徐主恩
王志华
吴继英
陶春芳
王树云
XU Zhuen WANG Zhihua WU Jiying TAO Chunfang WANG Shuyun(Emergency Department of Pudong Hospital, Shanghai 201301, China)
出处
《上海医药》
CAS
2016年第24期21-22,31,共3页
Shanghai Medical & Pharmaceutical Journal
关键词
脑梗死
尿激肽原酶
疗效
cerebral infarction
urinary kallidinogenase
treatment effect
